Prometheus Biosciences, Inc. Common Stock
RXDX
RXDX was delisted on the 15th of June, 2023.
219 hedge funds and large institutions have $4.35B invested in Prometheus Biosciences, Inc. Common Stock in 2023 Q1 according to their latest regulatory filings, with 40 funds opening new positions, 92 increasing their positions, 71 reducing their positions, and 39 closing their positions.
267% more call options, than puts
Call options by funds: $110M | Put options by funds: $29.9M
30% more repeat investments, than reductions
Existing positions increased: 92 | Existing positions reduced: 71
4% more capital invested
Capital invested by funds: $4.19B → $4.35B (+$166M)
3% more first-time investments, than exits
New positions opened: 40 | Existing positions closed: 39
1% less funds holding
Funds holding: 221 → 219 (-2)
24% less funds holding in top 10
Funds holding in top 10: 17 → 13 (-4)
Top Buyers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
FCM
Farallon Capital Management
San Francisco,
California
|
+$110M |
| 2 |
Vanguard Group
Malvern,
Pennsylvania
|
+$99.1M |
| 3 |
T. Rowe Price Associates
Baltimore,
Maryland
|
+$49.5M |
| 4 |
Fidelity Investments
Boston,
Massachusetts
|
+$45M |
| 5 |
Westfield Capital Management
Boston,
Massachusetts
|
+$42.2M |
Top Sellers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
Adage Capital Partners
Boston,
Massachusetts
|
-$78.4M |
| 2 |
CAM
Cormorant Asset Management
Boston,
Massachusetts
|
-$50.1M |
| 3 |
EAM
Eventide Asset Management
Boston,
Massachusetts
|
-$41.8M |
| 4 |
APM
Avidity Partners Management
Dallas,
Texas
|
-$22.4M |
| 5 |
Franklin Resources
San Mateo,
California
|
-$21.6M |
RXDX Hedge Fund Activity: Q1 2023 in Review
219 of the 6,277 institutional investors tracked by Wall St. Rank reported a position in Prometheus Biosciences, Inc. Common Stock (RXDX) for Q1 2023, worth a combined $4.35B — up 4% from $4.19B a quarter earlier.
Buyers outnumbered sellers: 40 funds opened new RXDX positions and 39 closed out — a net gain of 1 holder — while 92 added to existing stakes and 71 trimmed.
The largest buyer was Farallon Capital Management, adding an estimated $110M. The largest seller was Adage Capital Partners, cutting an estimated $78.4M.
- 219 institutional investors held Prometheus Biosciences, Inc. Common Stock (RXDX) as of Q1 2023, down from 221 in Q4 2022.
- Funds reported $4.35B of Prometheus Biosciences, Inc. Common Stock stock for Q1 2023, up 4% quarter-over-quarter.
- 40 funds opened new Prometheus Biosciences, Inc. Common Stock positions in Q1 2023 and 39 closed out, a net change of +1 holder.
- The largest Prometheus Biosciences, Inc. Common Stock buyer in Q1 2023 was Farallon Capital Management, an estimated $110M added.
- The largest Prometheus Biosciences, Inc. Common Stock seller in Q1 2023 was Adage Capital Partners, an estimated $78.4M sold.
Based on aggregated 13F filings for Q1 2023.